Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Interest & Investment Income (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Interest & Investment Income for 16 consecutive years, with $118000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Interest & Investment Income fell 84.14% to $118000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.7 million, a 25.37% decrease, with the full-year FY2025 number at $1.7 million, down 25.37% from a year prior.
  • Interest & Investment Income was $118000.0 for Q4 2025 at Anika Therapeutics, down from $997000.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $997000.0 in Q3 2025 to a low of -$154000.0 in Q1 2022.
  • A 5-year average of $342950.0 and a median of $410500.0 in 2024 define the central range for Interest & Investment Income.
  • Biggest YoY gain for Interest & Investment Income was 1008.33% in 2022; the steepest drop was 258.14% in 2022.
  • Anika Therapeutics' Interest & Investment Income stood at -$47000.0 in 2021, then soared by 687.23% to $276000.0 in 2022, then skyrocketed by 109.06% to $577000.0 in 2023, then increased by 28.94% to $744000.0 in 2024, then crashed by 84.14% to $118000.0 in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Interest & Investment Income are $118000.0 (Q4 2025), $997000.0 (Q3 2025), and $214000.0 (Q2 2025).